Irwin H. Gelman
Irwin H. Gelman
Professor

Roswell Park Cancer Institute
USA

Education

Biochemistry BA 1980 Wesleyan University, Connecticut, New York
Microbiology MA 1983 Columbia University   , New York,USA
Microbiology MPhil 1985 Columbia University   , New York,USA
Microbiology   PhD 1987 Columbia University   , New York,USA
American Cancer Society Postdoctoral Associate 1987-1991 The Rockefeller University, New York, USA

 

Biography

Irwin Gelman received his B.A. in Biochemistry from Wesleyan University (CT) followed by M.A., M.Phil. and Ph.D. degrees in Microbiology from Columbia University.  He was an American Cancer Society Postdoctoral Associate in the lab of HidesaburoHanafusa at The Rockefeller University, studying how the Src oncogene encoded by Rous sarcoma virus induces cancer and metastasis.  He then joined the faculty of the Departments of Microbiology and Infectious Diseases at Mount Sinai School of Medicine in 1990, and in 1996, became a member of the Ruttenberg Cancer Center at Mount Sinai.  In 2003, he was recruited to the Roswell Park Cancer Institute, where he is now the John and Santa Palisano Chair of Cancer Genetics, Professor of Oncology and Chair of the RPCI-Cell and Molecular Biology Academic Program at the State University of New York at Buffalo, Leader of the Genetics Program of the Roswell Park Comprehensive Cancer Center, and Director of the shRNA Core lab at Roswell Park.He has served on multiple National Institutes of Health, Department of Defense and foundation grant and programmatic study sections, on the National Functional Genomics Center advisory board, and on the Scientific Advisory Board of Kinex Pharmaceuticals, LLC.  He currently also serves as an Associate Editor of the journalsCancer Research, Oncogene and Journal of Cancer Biology & Research.  His funding from the NIH, DOD and the Alliance Foundation focuses on the role of SSeCKS/AKAP12 metastasis suppressor in prostate cancer, the role of Src-family kinases in promoting androgen receptor-dependent, castration-recurrent prostate cancer, and the identification and characterization of novel metastasis-regulating genes in breast and prostate cancer using genomic screens. 

 

Research Interest

My lab mainly focuses on studying how Src-family and FAK tyrosine kinases control oncogenesis and metastasis in clinically-relevant prostate and breast cancer models through signaling and cytoskeletal pathways.  To this end, our lab performs many genetic screens such as with genomic shRNA, to identify and characterize potential metastasis suppressors.  An example is SSeCKS/Gravin/AKAP12, which is downregulated in human prostate cancer metastases, and which suppresses prostate cancer metastasis by scaffolding Src, PKC, calmodulin and cyclins and attenuating their signaling pathways.  We have also begun to identify genes that control prostate and breast cancer invasiveness and suppression of dormancy in bone environments, as well as genes that control metastasis through their expression in tumor microenvironmental cells.  Another example is FOXO4, which suppresses prostate cancer cell invasiveness by preventing the aggressiveness factor, RUNX2, from transactivating pro-metastatic genes.

 

Professional Activities:

 

Publications

  1. Zerial, A., Gelman, I., Firshein, W. Glycolipids stimulate DNA polymerase activity in a DNA-membrane fraction and in a partially purified polymerase system extracted from pneumococcus. J Bact 135:78-85, 1978.
  2. Firshein, W., Gelman, I. Enrichment of DNA polymerase III in a DNA-Membrane complex purified from pneumococcus: the possible existence of subcomplexes. Mol Gen Genet 182:87-96, 1981.
  3. Gelman, I.H. and Silverstein, S. Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene. Proc Natl Acad Sci 82:5265-5269, 1985.
  4. Gelman, I.H. and Silverstein, S. Coordinate regulation of herpes simplex virus gene expression is mediated by the functional interaction of two immediate early gene products. J Mol Biol 191:395-409, 1986.
  5. Gelman, I.H. and Silverstein, S. Herpes simplex virus immediate-early promoters are responsive         to virus and cell trans-acting factors. J Virol 61:2286-2296, 1987.
  6. Gelman, I.H., Silverstein, S. Dissection of immediate-early gene promoters from herpes simplex virus: sequences that respond to the virus transcriptional activators. J Virol 61:3167-3172, 1987.
  7. Gelman, I.H., and Hanafusa, H. Suppression of rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel n-termini. J Virol 63:2461-2468, 1989.
  8. Kemp, L.M., Gelman, I.H., Silverstein S.J., Latchman, D.S. Regulation of HSV immediate-early promoters in mouse neuroblastoma cells.  Neurosci Lett 118:185, 1990.
  9. Gelman, I. H., Zhang, J., Heilman, P.E., Hanafusa, H., Morse, S.S. Identification and Evaluation of new primer sets for the detection of lentivirus proviral DNA. AIDS Res. Human Retrovir 8:1981-1989, 1992.
  10. Laurence, J., Siegal, F.P., Schattner, E., Gelman, I.H., Morse, S. Individuals with acquired immune deficiency without evidence for human immunodeficiency virus types-1, -2 by serology, culture, and DNA amplification. Lancet 340:273-274, 1992. 
  11. Gelman, I.H. and Hanafusa, H. src-Specific immune regression of rous sarcoma virus-induced tumors. Cancer Res 53:915-920, 1993.
  12. Bohensky, R.A., Papavassiliou, A.G., Gelman, I.H., Silverstein, S. Identification of a promoter mapping within the reiterated sequences that flank the Herpes Simplex Virus type 1 UL region. J Virol 67:632-642, 1993.
  13. Gelman, I.H., Khan, S., Hanafusa H. Morphological transformation, tumorigenicity, and src-specific CTL-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristoylated N-terminal domains. Oncogene 8:2995-3004, 1993.
  14. Frankfort, B. and Gelman, I.H. Identification of novel cellular genes transcriptionally suppressed by v-src. BBRC 206:916-926, 1995.
  15. Lin, X., Nelson, P., Van Tuyl, A., Johnson, R., Gelman, I.H. Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in src- and ras-transformed cells.  Mol Cell Biol 15(5):2754-2762, 1995.
  16. Lin, X., Tombler, E., Nelson, P., Ross., M., Gelman, I.H. A Novel src- and ras-suppressed protein kinase C substrate associated with cytoskeletal architecture. J Biol Chem 271(45):28430-28438, 1996.
  17. Lin, X., and Gelman, I.H.  Re-expression of the major protein kinase C substrate, SSeCKS, suppresses v-src induced morphological transformation and oncogenic growth. Cancer Res 57(11):2304-2312, 1997.
  18. Nelson, P. and Gelman, I.H.  Cell-cycle regulated expression and serine phosphorylation of the myristylated protein kinase C substrate, SSeCKS: Correlation with cell confluency, G0 phase and serum response.  Molec Cell Biochem 175:233-241, 1997. 
  19. Gelman, I.H., Lee, K., Tombler, E., Gordon, R., Lin, X. Control of cytoskeletal architecture by the src-suppressed c kinase substrate, SSeCKS.  Cell Motil Cytoskeleton 41(1): 1-17, 1998.
  20. Nelson, P., Moissoglu, K., Vargas, J., Jr., Klotman, P.E., Gelman, I.H. The protein kinase C substrate, SSeCKS, controls actin-based stellate morphology in mesangial cells. J Cell Sci. 112:361-370, 1999.
  21. Gelman, I.H., Qiaoran X.I., Kumar C.C. Re-expression of the major PKC substrate, SSeCKS, correlates with the tumor suppressive effects of SCH51344 on Rat-6/src and Rat-6/ras fibroblasts but not on Rat-6/raf fibroblasts.  NY Acad Sci 886:221-224, 1999.
  22. Gelman, I.H., Tombler, E., Vargas, J., Jr. developmental and tissue-specific expression of SSeCKS, a major PKC substrate with tumor suppressor activity, suggests roles in cytoskeletal architecture, formation of migratory processes and cell migration during embryogenesis. Histochem J 32:13-26, 2000.
  23. Gelman, I.H., Unger, E.R., Mawle, A., Nusenbaum, R., Reeves W.C.  Chronic fatigue syndrome is not associated with the expression of endogenous retroviral p15E.   Mol  Diagn 5:155-156, 2000.
  24. Lin, X., Nelson, P, Gelman, I.H. Regulation of G1->S progression by the SSeCKS tumor suppressor: control of cyclin d expression and cellular compartmentalization.  Molec Cell Biol 20(19):7259-7272, 2000.
  25. Gelman, I.H., Lin, X., Nelson, P.J.  SSeCKS controls G1->S progression by modulating cyclin D expression and cellular compartmentalization. Molec Biol Cell 11S:341a, 2000.
  26. Cohen, S. B., Waha, A., Gelman, I.H., Vogt, P.K., Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts. Oncogene 20:141-146, 2001.
  27. Rombouts, K.,  Knittel, T., Wielant, A., Piscaglia, F., Machesky L., Hellemans K., Gelman, I., Ramadori G., Geerts, A. Effect of Trichostatin A, a histone deacetylase inhibitor, on proteins of the actin cytoskeleton", in Cells of the Hepatic Sinusoid, E. Wisse, D.L. Knook, R. de Zanger, M.J.P. Arthur (Eds, The Kupffer Cell Foundation, The Netherlands, 8:271-273, 2001.
  28. Wassler, M.J., Foote, C.I., Gelman, I.H., Shur, B.D. Functional interaction between cell surface a-1,4-galactosyltransferase and SSeCKS, a PKC substrate. J Cell Sci 114:2291-2300, 2001.
  29. Xia, W., Unger, P., Miller, L., Nelson, P.J., Gelman, I.H., Suppression of prostate metastasis by re-expression of the Src-suppressed C kinase substrate, SSeCKS. Cancer Res 61:5644-5651, 2001.
  30. Nelson, P.J., Gelman, I.H., Klotman, P.E. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinase promotes differentiation of infected podocytes. J Am Soc Nephrol 12:2827-2831, 2001.
  31. Lin, X. and Gelman, I.H. Calmodulin and cyclin D anchoring sites on the Src-suppressed C kinase substrate, SSeCK.  Biochem Biophys Res Commun 290:1368-1375, 2002. 
  32. Cara, A., Vargas, J., Jr., Keller,M., Jones, S., Mosoian, A., Gurtman, A., Cohen, A., Parkas, A., Wallach, F., Chusid, E., Gelman, I.H., Klotman, M.E.  Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma viral HIV RNA.  Virol 292:1-5, 2002.
  33. Xia, W. and Gelman, I.H. Mitogen- and FAK-regulated tyrosine phosphorylation of the SSeCKS scaffolding protein modulates its actin-binding properties.  Exp Cell Res 277(2):139-151, 2002.
  34. Husain, M., Gusella, G.L., Klotman, M.E., Gelman, I.H., Ross, M.D., Schwartz, E.J., Cara, A., Klotman, P.E. HIV-1 Nef induces anchorage-independent growth of cultured podocytes. J  Am Soc Nephrol 13:1806-1815, 2002.
  35. Rombouts, K., Knittel, T., Wielant, A., Piscaglia, F., Machesky, L., Hellemans, K., Gelman, I., Ramadori, G., Geerts A. Actin filament formation, migration and contraction are impaired in hepatic stellate cells under the influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol 37:788-796, 2002.
  36. Nelson, P.J., Sunamoto, M., Husain, M., Gelman, I.H. HIV-1 expression induces cyclin D1 expression and activity in infected podocytes: a mechanism for the proliferative phenotype in HIV-associated nephropathy.  BioMed Central Microbiol 2:26-36, 2002.
  37. Sperber, K., Beuria, P., Singha, N., Gelman, I., Cortes, P., Chen, H., Kraus, T. Induction of apoptosis by HIV-1 in infected monocytic cells. J Immunol 170:1566-1578, 2003.
  38. Nelson, P.J., D'Agati, V., Gries, J.-M., Suarez, J.R., Gelman, I.H., Amelioration of nephropathy in mice expressing HIV-1 gene by the potent cyclin-dependent kinase inhibitor, flavopiridol. J Antimicrob Chemother 51:921-929, 2003.
  39. Lee, S.W., Kim, W.J., Choi, Y.K., Song, H.S., Son M.J., Gelman, I.H., Kim, Y.J., Kim, K.W. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrie. Nat Med 9:900-906, 2003.
  40. Moissoglu, K. and Gelman, I.H. v-Src rescues actin-based cytoskeletal architecture and cell motility, and induces enhanced anchorage-independence during oncogenic transformation of FAK-Null fibroblasts. J Biol Chem 278:47946-47959, 2003.
  41. Gherardi, D., D'Agati, V.D., Chu, T-H.T., Barnett, A., Gianella-Borradori, A., Gelman, I.H., Nelson, P.J. Reversal of collapsing glomerulonephropathy in mice with the cyclin-dependent kinase inhibitor, CYC202. J Am Soc Nephrol 15:1212-1222, 2004.
  42. Streb, J.W., Kitchen, C.M., Gelman, I.H., Miano, J.M. Multiple promoters direct expression of the three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. J Biol Chem 279:56014-56023, 2004.
  43. Moissoglu, K., Sachdev, S and Gelman, I.H. Enhanced v-Src-induced oncogenic transformation in the absence of focal adhesion kinase is mediated by phosphatidylinositol 3-kinase.  Biochem Biophys Res Commun 330:673-684, 2005.
  44. Greenberg, R.S., Bernstein, A.M., Benezra, M., Gelman, I.H., Taliana, L.D., Masur, S.K. FAK-dependent regulation of myofibroblast differentiation. FASEB J 20(7):1006-1018, 2006.
  45. Gelman, I.H. and Gao, L. The SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via rhoa- and Cdc42-dependent pathways. Mol Cancer Res 4(3):151-158, 2006.  Cover Photograph
  46. Su, B., Zheng, Q., Vaughan, M.M., Bu, Y., Gelman, I.H. SSeCKS metastasis-suppressing   activity correlates with VEGF inhibition. Cancer Res 66(11):5599-5607, 2006.
  47. Liu, Y. and Gelman, I.H. SSeCKS/Gravin/AKAP12 reprograms proliferative/angiogenic gene expression during suppression of v-Src-Induced oncogenesis.  BMC Cancer, 6:105-117, 2006. PMCID: PMC1463002.
  48. Chaar, Z.Y., O'Reilly, P., Gelman, I.H., Sabourin, L.A.., v-src-dependent downregulation of the ste20-like kinase SLK by casein kinase II.  J Biol Chem 281:28193-28199, 2006.
  49. Bu, Y. and Gelman, I.H. v-Src-mediated downregulation of the SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1/Sp1/Sp3 complex.  J Biol Chem 282(37):26725-39, 2007.
  50. Gelman IH. AKAP12 (A kinase (PRKA) anchor protein 12). Atlas Genet Cytogenet Oncol Haematol. 2007;11(2):80-83.
  51. Akakura, S., Huang, C., Nelson, P.J., Foster, B., Gelman, I.H. Loss of the ssecks/gravin/akap12 gene results in prostatic hyperplasia.  Cancer Res 68:5096-5103, 2008. PMCID: PMC2839164
  52. Lau G.M., Lau G.M., Yu G.L., Gelman I.H., Gutowski A., Hangauer D., Fang J.W., Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro, Dig Dis Sci 54(7):1465-1474, 2009. 
  53. Song L., Ohnuma T., Gelman I.H., Holland, J.F., Reovirus infection of cancer cells is not due to the activated Ras pathway. Cancer Gene Therap 16(4):382, 2009. 
  54. Sachdev S., Bu Y., Gelman I.H., Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.  BMC Cancer 9:12-26, 2009. PMCID: PMC2651180
  55. Su, B., Bu, Y., Engelberg, D. and Gelman, I.H. “SSeCKS/Gravin/AKAP12 inhibits cancer cell invasion and chemotaxis by suppressing a PKC-Raf/MEK/ERK pathway”. J Biol Chem, 285:4578-86, 2010. PMCID: PMC2836062
  56. Akakura, S., Nochajski, P., Gao, L., Sotomayor, P., Matsui, S.-I. and Gelman, I.H., “Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC scaffolding by SSeCKS/AKAP12”, Cell Cycle, 9(23):4656-65. 2010.  Cover photoNews and Views, “Unbearable stress: Collapse of the SSeCKS/AKAP12 scaffold leads to senescence and transformation”, Hinds, P. Cell Cycle, vol. 10 (17), Sept. 1, 2011.  PMCID: PMC3048035
  57. Bu, Y., Gao, L., Gelman, I.H., “Role For Transcription Factor TFII-I in the Suppression of SSeCKS/Gravin/Akap12 Transcription By Src”, Int. J. Cancer, 128(8):1836-42, 2011. doi: 10.1002/ijc.25524. PMCID: PMC2997892.
  58. Streb, J.W., Long, X., Lee, T.-H., Sun, Q., Kitchen, C.M., Georger, M.A., Slivano, O.J., Blaner, W.S., Carr, D.W., Gelman, I.H., Miano, J., “Retinoid-Induced Expression and Activity of an Immediate Early Tumor Suppressor Gene in Vascular Smooth Muscle Cells”, Submitted, PLoS One, 6(4);e18538, 2011. doi:10.1371/journal.pone.0018538. PMCID: PMC3071728.
  59. Akakura, S., Bouchard, R., Bshara, W., Morrison, C. and Gelman, I.H., “Carcinogen-induced squamous papillomas and oncogenic progression in the absence of the SSeCKS/AKAP12 metastasis suppressor correlates with FAK upregulation”, Int. J. Cancer, 129(8):2025-2031, 2011. PMCID: PMC3107938.
  60. Guo, L.-W., Su, B., Gao, L. and Gelman, I.H., “Control of protein kinase C activity, phorbol ester-induced cytoskeletal remodeling and cell survival signals by the scaffolding protein SSeCKS/GRAVIN/AKAP12” J. Biol. Chem., 286(44):38,356-38,366, 2011. PMCID: PMC3207390.
  61. Burnworth, B., Pippin, J., Akakura, S., Krofft, R., Zhang, G., Hudkins, K., Alpers, C.E., Smith, K., Shankland, S., Gelman, I.H., and Nelson, P.J., "SSeCKS sequesters cyclin D1 in glomerular parietal epithelial cells", Lab Invest., 92(4):499-510, 2012. Impact factor = 3.828.
  62. Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG. A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively  inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis, 33(5):1004-1013, 2012.  PMCID: PMC3334519. Impact factor = 5.815.
  63. Gelman, I.H., “Missing Methods” in News and Opinion, The Scientist, http://the-scientist.com/2012/05/03/opinion-missing-methods/, May 3, 2012. 
  64. Ho, B., Olson, O., Figel, S., Gelman, I., Cance, W., Golubovskaya, V. “Nanog increases Focal adhesion kinase (FAK) promoter activity and expression, and directly binds to FAK protein to be phosphorylated”, J Biol Chem, 287(22)18656-73, 2012. PMCID: PMC3365765.  Impact factor = 7.25. 
  65. Su, B., Gao, L., Meng, F., Guo, L-W., Rothschild, J., Gelman, I.H., Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene, 32(16):2016-2026, 2013. PMCID: PMC3449054.  Impact factor = 8.56. 
  66. Liu, X., Yang, N., Figel, S.A, Wilson, K.E., Morrison, C.D., Gelman, I.H., Zhang, J. PTPN14 interacts with and negatively regulates the oncogenic function of YAP.  Oncogene, 32(10):126601273, 2013.  Impact factor = 8.56. 
  67. Havekes R, Canton DA, Park AJ, Huang T, Nie T, Day JP, Guercio LA, Grimes Q, Luczak V, Gelman IH, Baillie GS, Scott JD, Abel T.  Gravin Orchestrates Protein Kinase A and β2-Adrenergic Receptor Signaling Critical for Synaptic Plasticity and Memory. J Neurosci. 32(50):18137-49, 2012. doi: 10.1523/JNEUROSCI.3612-12.2012.  Highlighted in: The J Neurosci, 32(50):18137-18149.  PMCID: PMC3533251.  Impact factor = 6.91. 
  68. Smeets B, Boor P, Dijkman H, Sharma SV, Jirak P, Mooren F, Berger K, Bornemann J, Gelman IH, Floege J, van der Vlag J, Wetzels JF, Moeller MJ. Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. J Pathol. 229(5):645-659, 2013.  PMCID: 3951144. Impact factor = 7.33. 
  69. Schulte, K., Berger, K., Boor, P., Jirak, P., Gelman, I.H., Arkill, K.P., Neal, C.R., Kriz. W., Floege, J., Smeets, B., Moeller, M.J., Origin of Parietal Podocytes in Atubular Glomeruli Mapped by Lineage Tracing. J Am Soc Nephrol. 2014, 25(1):129-141.  PMID:24071005. Impact factor = 8.99. 
  70. Su, B., Gillard, B., Gao, L., Eng, K.H., Gelman, I.H., Src controls castration-recurrence of
  71. CWR22 prostate cancer xenografts. Cancer Medicine, 2(6):784-192, 2013. PMCID: 3892383.  Impact factor = 2.84. 

  72. Ko, H.-K. Akakura, S., Peresie, J., Goodrich, D.W., Foster, B.A., Gelman, I.H., A transgenic model for early prostate metastasis to lymph nodes, Cancer Research, 74:945, 2014.  PMCID: 3892383. Impact factor = 9.28.  **4th most cited papers from Cancer Res. 2013-2014 (http://cancerres.aacrjournals.org/reports/most-cited). 
  73. Cha JH, Wee HJ, Seo JH, Ahn BJ, Park JH, Yang JM, Lee SW, Kim EH, Lee OH, Heo JH Lee HJ, Gelman IH, Ken Arai K, Lo EH, Kim KW, AKAP12 mediates barrier functions of fibrotic scars during CNS repair. PLoS ONE, 2014, 9(4):e94695. PMCID: PMC3997571. Impact factor = 3.53. 
  74. Sheila Figel Dwyer and I.H. Gelman, Cross-phosphorylation and interaction between Src/FAK and MAPKAP5/PRAK in early focal adhesions controls cell motility, J Cancer Biol Res., 2014, 2(1):1045.
  75. Su, B., Gao, L., Baranowski, C., Gillard, B., Wang, J., Ransom, R., Ko, H.-K., Gelman, I.H. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer, PLoS ONE, 2014, 9(7):e101411.  Impact factor = 3.53. 
  76. Gelman, I.H., Peresie, J., Eng, K.H., Foster, B.A., Differential Requirement for Src-family Tyrosine Kinases in the Initiation, Progression and Metastasis of Prostate Cancer, Molec. Cancer Res., 2014, 12(10):1470-9. Impact factor = 4.50. 
  77. Jong-Ho Cha, Hee-Jun Wee, Ji Hae Seo, Bum Ju Ahn, Ji-Hyeon Park, Jun-Mo Yang, Sae-Won Lee, Ok-Hee Lee, Hyo-Jong Lee, Irwin H. Gelman, Ken Arai, and Eng Lo, Kyu-Won Kim, Prompt meningeal reconstruction mediated by oxygen-sensitive AKAP12 scaffolding protein after central nervous system injury, Nature Commun, 2014, 5:e4952. doi:10.1038/ncomms5952. Impact factor = 10.74. 
  78. Irwin H. Gelman, Beyond the Abstract: A transgenic mouse model for early prostate metastasis to lymph nodes, Uro Today, October 14, 2014, http://www.urotoday.com/Prostate-Cancer/a-transgenic-mouse-model-for-early-prostate-metastasis-to-lymph-nodes-beyond-the-abstract-by-irwin-h-gelman-phd.html
  79. Ko, H.-K., Guo, L.-W., Su, B., Gao, L., Gelman, I.H., Suppression of chemotaxis by SSeCKS via scaffolding of phosphoinositol phosphates and the recruitment of the Cdc42 GEF, Frabin, to the leading edge, PLoS ONE, 2014, 9(10):e111534. Impact factor = 3.53. 
  80. Dwyer, S.F., Gao, L and Gelman, I.H., Identification of Novel Focal Adhesion Kinase Substrates: Role for FAK in NFκB Signaling.  Int J Biol Sci, 2015, 11(4):404-410.  Impact factor = 4.372.
  81. Hehnly, H., Canton, D., Bucko, P., Langeberg, L., Ogier, L., Gelman, I., Santana, L., Wordeman, L., Scott, J. A mitotic kinase scaffold depleted in testicular seminomas impacts spindle orientation in germline stem cells, eLife, 2015, 4:e09384. Impact factor = 9.322. 

cancer-research Journal Flyer